Key facts
- Bambusa Therapeutics’s last known valuation is $555.0M (Oct 2025).
- It has raised $143.0M across 4 recorded rounds; the latest was Early Stage VC (Series A2) ($40.0M) in Oct 2025.
- Notable investors include RA Capital Management, The Invus Group, INCE Capital, Redmile Group, Salvia (Holzkirchen) — 11 tracked in total.
- Bambusa Therapeutics has filed 3 Form Ds with the SEC, most recently Feb 2025 ($53.3M sold to 16 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Bambusa Therapeutics
Funding rounds
4 roundsAbout Bambusa Therapeutics
Operator of a biotechnology company intended to create bispecific antibodies for treating immunological and inflammatory disorders. The company specializes in building a diverse portfolio of molecules and using antibody development capabilities to provide targeted therapies, enabling the healthcare industry to treat patients suffering from debilitating and chronic inflammatory conditions.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2024
- Employees
- 12
- Website
- bambusatx.com/
- Ownership
- Privately Held (backing)
Bambusa Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bambusa Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bambusa Therapeutics in its N-PORT filings yet. We sweep new filings monthly.